Australian medtech startup Oli secures $6.5 M to advance predictive maternal and foetal monitoring

Oli aims to have the ability to analyse up to fifteen conditions and complications across pregnancy and birth

Oli, a wireless, wearable device that monitors maternal and fetal signals, has secured $6.5 million in funding to accelerate development of its technology and support regulatory and clinical progress across Australia and the United States ahead of launch.

The funding will support the completion of pivotal clinical trials underway across seven sites in Australia and the United States, advancement of regulatory submissions with the Therapeutic Goods Administration (TGA) and the US Food and Drug Administration (FDA), as well as business operations, and the establishment of manufacturing operations and headquarters in Australia.

The Series A3 round, backed by Scale Investors, Clare Ventures and The University of Sydney, follows a $1.8 million Series A2 in 2024 and a $4.7 million Series A in 2022. To date, Oli has raised $13 million in private capital, alongside more than $9.5 million in non-dilutive grants.

Oli aims to have the ability to analyse up to fifteen conditions and complications across pregnancy and birth, including postpartum haemorrhage (PPH), fetal distress, stillbirth risk and labour progression.

Oli’s dual-market strategy positions Australia as a key launchpad for clinical adoption and innovation, while targeting the significant scale opportunity in the United States, where rising maternal mortality and PPH rates are driving urgent demand for data-driven, preventative care solutions.

Published on : 01st June, 2026